Ahmet Dirican, MD
Geriatric Medicine · New Bedford, MANPI 1396723813
Payments from drug & device makers
Across 599 payments — averaging $3016.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$682K
- Astrazeneca UK Limited$245K
- AstraZeneca$191K
- Eli Lilly$134K
- Lexicon Pharmaceuticals, Inc.$115K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$109K
- plus $331K from 26 others
Across 28 payments — averaging $4820.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$123K
- Purdue Pharma L.p.$8K
- Lexicon Pharmaceuticals, Inc.$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 161 | $682,124 |
| Astrazeneca UK Limited | 4 | $245,018 |
| AstraZeneca | 16 | $191,230 |
| Eli Lilly | 11 | $133,512 |
| Lexicon Pharmaceuticals, Inc. | 53 | $114,744 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $108,983 |
| Amgen | 3 | $90,757 |
| Janssen Research & Development, LLC | 29 | $79,852 |
| Novo Nordisk AS | 170 | $48,882 |
| Abbott | 10 | $28,368 |
| Chiesi USA, Inc. | 10 | $21,444 |
| Vanda Pharmaceuticals Inc. | 1 | $20,500 |
| Supernus Pharmaceuticals, Inc. | 6 | $17,525 |
| Adlon Therapeutics L.p. | 1 | $7,300 |
| Evofem Biosciences, Inc. | 5 | $7,180 |
| Alnylam Pharmaceuticals Inc. | 60 | $6,264 |
| Purdue Pharma L.p. | 1 | $1,000 |
| Otsuka America Pharmaceutical, Inc. | 6 | $628 |
| Novo Nordisk | 3 | $313 |
| Johnson & Johnson | 12 | $311 |
| Bayer | 3 | $244 |
| E.r. Squibb & Sons, L.L.C. | 3 | $228 |
| Sunovion Pharmaceuticals Inc. | 9 | $169 |
| Mylan Specialty L.p. | 2 | $144 |
| Astellas Pharma US Inc | 2 | $140 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Gilead | 1 | $32 |
| Radius Health, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| GSK | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$1,807,023 in reported general payments places this provider in the 95th percentile of 156 geriatric medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other geriatric medicine in New Bedford
- Irving RestituyoNew Bedford$9K
- Efrain TorresNew Bedford$882
- Ana Cecilia CuryBoston$1.7M
- Medha MunshiBoston$276K
- W Vincent PerrelliWaltham$64K
- Asif MerchantChelmsford$6K
- Rocco RossiMashpee$6K
- Douglas KielBoston$6K
- Lilian MikaelConcord$5K
- Michael CantorBraintree$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.